A multicenter, phase 2, randomized, double-blinded, placebo-controlled study of dimebon in subjects with Huntington's disease /DIM05

The Huntington Study Group (HSG) is conducting a study of the research medication dimedon in subjects 18 years of age or older who have mild to moderate Huntingon's disease (HD). This study is designed to determine the effect of dimedon on thinking, movement and overall functioning of people with HD. Approximately 15 research centers in the United States and the United Kingdom will enroll up to 90 research subjects. The study will last about three months. The study will enroll research subjects with early to moderate signs of HD who can walk without assistance and who are self-sufficient in activities of daily living (such as eating, dressing and bathing).

You may be eligible to participate in this study if you:

• Are 18 years of age or older
• Have clinical features of HD and a confirmatory family history of HD; and/or genetically confirmed HD
• Are independently walking and self-sufficient in activities of daily living (eating, dressing, bathing)
• Are able to take medication (capsules) by mouth

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.